441 related articles for article (PubMed ID: 10414730)
1. Temporary intraurethral prostatic bridge-catheter compared with neoadjuvant and adjuvant alpha-blockade to improve early results of high-energy transurethral microwave thermotherapy.
Djavan B; Ghawidel K; Basharkhah A; Hruby S; Bursa B; Marberger M
Urology; 1999 Jul; 54(1):73-80. PubMed ID: 10414730
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant and adjuvant alpha-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial.
Djavan B; Shariat S; Fakhari M; Ghawidel K; Seitz C; Partin AW; Roehrborn CG; Marberger M
Urology; 1999 Feb; 53(2):251-9. PubMed ID: 9933035
[TBL] [Abstract][Full Text] [Related]
3. [Prevention of temporary prostatic obstruction after high-energy microwave thermothery by placement of prostatic bridge catheter].
Djavan B; Seitz C; Fakhari M; Ghawidel K; Marberger M
Prog Urol; 1999 Apr; 9(2):261-70. PubMed ID: 10370950
[TBL] [Abstract][Full Text] [Related]
4. A novel intraurethral prostatic bridge catheter for prevention of temporary prostatic obstruction following high energy transurethral microwave thermotherapy in patients with benign prostatic hyperplasia.
Djavan B; Fakhari M; Shariat S; Ghawidel K; Marberger M
J Urol; 1999 Jan; 161(1):144-51. PubMed ID: 10037387
[TBL] [Abstract][Full Text] [Related]
5. Microwave thermotherapy for benign prostatic hyperplasia.
Hoffman RM; Monga M; Elliott SP; Macdonald R; Langsjoen J; Tacklind J; Wilt TJ
Cochrane Database Syst Rev; 2012 Sep; (9):CD004135. PubMed ID: 22972068
[TBL] [Abstract][Full Text] [Related]
6. Microwave thermotherapy for benign prostatic hyperplasia.
Hoffman RM; Monga M; Elliot SP; Macdonald R; Wilt TJ
Cochrane Database Syst Rev; 2007 Oct; (4):CD004135. PubMed ID: 17943811
[TBL] [Abstract][Full Text] [Related]
7. Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Franco JV; Garegnani L; Escobar Liquitay CM; Borofsky M; Dahm P
Cochrane Database Syst Rev; 2021 Jun; 6(6):CD004135. PubMed ID: 34180047
[TBL] [Abstract][Full Text] [Related]
8. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
9. High-energy transurethral microwave thermotherapy in patients with acute urinary retention due to benign prostatic hyperplasia.
Djavan B; Seitz C; Ghawidel K; Basharkhah A; Bursa B; Hruby S; Marberger M
Urology; 1999 Jul; 54(1):18-22. PubMed ID: 10414720
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
11. Transurethral microwave thermotherapy: what role should it play versus medical management in the treatment of benign prostatic hyperplasia?
Djavan B; Larson TR; Blute ML; Marberger M
Urology; 1998 Dec; 52(6):935-47. PubMed ID: 9836535
[TBL] [Abstract][Full Text] [Related]
12. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Singh DV; Mete UK; Mandal AK; Singh SK
J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of high-energy transurethral microwave thermotherapy in alleviating medically refractory urinary retention due to benign prostatic hyperplasia.
Kellner DS; Armenakas NA; Brodherson M; Heyman J; Fracchia JA
Urology; 2004 Oct; 64(4):703-6. PubMed ID: 15491705
[TBL] [Abstract][Full Text] [Related]
14. Our experience with the treatment of benign prostatic hyperplasia (BPH) with tamsulosin.
Cervenakov I; Fillo J
Bratisl Lek Listy; 2001; 102(3):138-41. PubMed ID: 11433602
[TBL] [Abstract][Full Text] [Related]
15. Durability of 30-minute high-energy transurethral microwave therapy for treatment of benign prostatic hyperplasia: a study of 213 patients with and without urinary retention.
Gravas S; Laguna P; Kiemeney LA; de la Rosette JJ
Urology; 2007 May; 69(5):854-8. PubMed ID: 17482921
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia.
Djavan B; Roehrborn CG; Shariat S; Ghawidel K; Marberger M
J Urol; 1999 Jan; 161(1):139-43. PubMed ID: 10037386
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study.
Lojanapiwat B; Permpongkosol S
Int Braz J Urol; 2011; 37(4):468-76. PubMed ID: 21888698
[TBL] [Abstract][Full Text] [Related]
18. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
Garimella PS; Fink HA; Macdonald R; Wilt TJ
Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
[TBL] [Abstract][Full Text] [Related]
19. Transurethral microwave thermotherapy for symptomatic benign prostatic hyperplasia: short-term experience with Prostcare.
Tsai YS; Lin JS; Tong YC; Tzai TS; Yang WH; Chang CC; Cheng HL; Lin YM; Jou YC
Urol Int; 2000; 65(2):89-94. PubMed ID: 11025430
[TBL] [Abstract][Full Text] [Related]
20. Feedback microwave thermotherapy with the ProstaLund Compact Device for obstructive benign prostatic hyperplasia: 12-month response rates and complications.
Alivizatos G; Ferakis N; Mitropoulos D; Skolarikos A; Livadas K; Kastriotis I
J Endourol; 2005; 19(1):72-8. PubMed ID: 15735388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
